Drug intelligence / Profile preview

PD-1 inhibitor + progesterone

Development stage: Unknown
Lead developer: Shanghai First Maternal and Infant Health Hospital
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral, Intramuscular

Overview

A combination therapy that pairs PD-1 checkpoint inhibitors with progesterone. PD-1 inhibitors work by blocking the interaction between PD-1 (programmed cell death protein 1) on T cells and PD-L1 on cancer cells, preventing immune suppression and enhancing T cell-mediated anti-tumor responses. Progesterone complements this action by inhibiting epithelial-to-mesenchymal transition (EMT), stimulating immune protection through increased tumor-infiltrating lymphocytes, and inhibiting proliferative pathways like PI3K/AKT and Wnt/β-catenin when progesterone receptors are present.

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on PD-1 inhibitor + progesterone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PD-1 inhibitor + progesterone.

Explore the full profile